Enhanced sensitivity HP-gas MRI/PET Dual Modality Imaging for Alzheimer's disease detection.

医学成像技术在各种疾病的早期诊断和管理以及临床研究和药物开发中发挥着至关重要的作用。医学成像系统的不断发展极大地提高了我们可视化身体组织和过程的能力，使我们能够更准确地检测医疗状况。然而，个性化医疗的最新趋势要求使用针对特定器官或疾病定制的器官特异性成像工具进行精确诊断的新方法。双模成像是该方法的组成部分，因为它提供了基于对齐的形态学和功能数据的互补视觉和定量信息，因此提供了最高的疗效和诊断能力。影响最大的领域之一是阿尔茨海默病（AD），其中需要精确成像来准确识别特定AD生物标志物的组合。这有望预测痴呆症患者的未来发展，并在现有治疗最有效的早期阶段诊断阿尔茨海默氏症的病理。对阿尔茨海默病改良治疗的临床试验和临床神经科学研究的患者进行分层队列也具有重要意义。该提案的总体目标是开发一种成像系统，该系统将脑专用正电子发射断层扫描（PET）与磁共振成像（MRI）相结合，用于精确的AD生物标志物引导医学。所提出的PET/MRI系统将通过结合PET的代谢和分子信息以及MRI的结构和功能信息，在提高AD的早期和鉴别诊断方面具有一些独特的优势。拟议的PET/MRI技术的商业化和临床应用将克服“一刀切”的阿尔茨海默病检测、干预和预防方法，并将推动阿尔茨海默病管理领域超越加拿大乃至全球目前的护理标准。

Medical imaging technologies play a crucial role in early diagnosis and management of a variety of diseases, aswell as in clinical research and drug development. Continued developments of medical imaging systems havevastly improved our ability to visualize body tissues and processes, enabling more accurate detection ofmedical conditions. However, recent trends for personalized medicine call for new approaches in precisiondiagnostics with organ-specific imaging tools customized for particular organs or diseases. Dual-modalityimaging is an integral part of this approach as it offers complimentary visual and quantitative information thatis based on aligned morphological and functional data and therefore provides the highest efficacy anddiagnostic capability.One of the biggest areas of impact is Alzheimer's Disease (AD) where precision imaging is required foraccurate identification of a combination of specific AD biomarkers. This holds a promise to predict the futuredevelopment of dementia in patients at risk and to enable the diagnosis of Alzheimer's pathology at the earlystages when available treatments are maximally effective. It is also of a high importance to stratify cohort ofpatients for clinical trials with AD modifying therapies and for clinical neuroscience research.The overarching goal of this proposal is to develop an imaging system that will combine brain-dedicatedPositron Emission Tomography (PET) with Magnetic Resonance Imaging (MRI) for precisionbiomarker-guided medicine in AD. The proposed PET/MRI system will have some unique advantages toimprove early and differential diagnosis of AD through combining the metabolic and molecular informationfrom PET and structural, functional information from MRI. The commercialization and clinical use of theproposed PET/MRI technology will overcome "one-size-fits-all" approach for AD detection, intervention andprevention, and will advance the field of AD management beyond the current standard of care in Canada, andglobally.